FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
 - EconoTimes)
NEW ORLEANS, Dec. 15, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 2, 2018 to file lead plaintiff applications in a securities class action lawsuit against Novan, Inc. (Nasdaq:NOVN), if they purchased the Company’s shares between the expanded period of September 26, 2016 and August 1, 2017 (the “Class Period”) and/or pursuant to its September 26, 2016 initial public offering (“IPO”). This action is pending in the United States District Court for the Middle District of North Carolina.
What You May Do
If you purchased shares of Novan and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nasdaqgm-novn/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 2, 2018.
About the Lawsuit
Novan and certain of its executives are charged with failing to disclose material information during the class period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had initiated and conducted two identical Phase 3 clinical trials for its lead product candidate SB204; (ii) in fact, the two SB204 Phase 3 clinical trials were not identical; and (iii) as a result of the foregoing, Novan’s financial statements were materially false and misleading at all relevant times.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
